Multiple solid tumors expressing B7H3 and PTK7
IDYAIDEAYA BiosciencesCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for IDE034 (B7H3/PTK7 TOP1 ADC) in Multiple solid tumors expressing B7H3 and PTK7. The expected timing is based on the latest available company guidance and may change.
02/27/26:- Ph1 IDE034 FPI reiterated; initial safety and PK readout planned; combo evaluation with IDE161 intended. 03/09/26:- May evaluate IDE034 as TOP1 ADC combo partner with IDE397 in MTAP-deleted cancers. 03/18/26:- Phase 1 IDE034 ongoing; AACR 2026 preclinical poster April 19, 2026. 03/30/26:- IDE161 combo rationale may enhance durability of TOP1 ADCs, including IDE034. 05/05/26:- IDE034 Ph1 dose escalation underway; first clinical data update from solid tumor trial targeted by YE 2026. 08/04/26:- IDE034 initial Ph1 data expected YE 2026 or Early 2027.
Verification
Confirm timing and program details against the company announcement or filing.